Launches BDENZA 160 mg strength critical to the treatment of Prostate Cancer

Mumbai : BDR Pharmaceuticals, well known for its most trusted and valuable brand ENZALUTAMIDE with brand name BDENZA launches the medicine in 160mg strength aiding the convenience of Prostate Cancer patients. This medicine was previously available in 40mg and 80mg strength for which patients had to consume 2 tablet a day as per approved dosage is primarily used to treat Prostrate Cancer patients.

The objective behind the launch of Enzalutamide 160mg is to ensure better efficacy, minimum side effects, contain relapse cases by blocking the hormones of cancer cells providing an evolved treatment.

Mr. Raheel Shah, Director Business Development from BDR Pharmaceuticals Int’l Pvt ltd, Mumbai said, “Our focused launch of such expanded brand strength will definitely add value to Indian Oncology patients as well as provide opportunity for Medical Physicians to comply with patient outcome and standard treatment protocol. This represents firm commitment to providing access to affordable medicines for Indian cancer patients with high a quality standard”.

Given the strength of BDR Pharma’s Oncology portfolio, another first time ever launch of Enzalutamide 160mg in its basket was awaited by many Indian Oncologist for the patient’s convenience. Patient will now have to consume only 1 tablet a day making it patient compliant, thereby reducing the associated stress of an already stressed out Cancer patient.

“As a key player in manufacturing of Indian Cancer medicines, BDR Pharmaceuticals propagates pan India affordability and is recognised as a “niche” entity in manufacturing of Pharmaceutical APIs and for the renowned new age formulations.”, said Mr. Shah.